| Literature DB >> 19880244 |
Ying-Ju Chen1, Chien-Lin Wu, Ju-Fang Liu, Yi-Chin Fong, Sheng-Feng Hsu, Te-Mao Li, Yi-Chang Su, Shing-Hwa Liu, Chih-Hsin Tang.
Abstract
Chondrosarcoma is a malignant primary bone tumor that responds poorly to both chemotherapy and radiation therapy. In the present study, we investigated the anti-cancer effect of a honokiol, an active component isolated and purified from the Magnolia officinalis in human chondrosarcoma cells. Honokiol-induced cell apoptosis in human chondrosarcoma cell lines (including: JJ012 and SW1353) but not primary chondrocytes. Honokiol also induces upregulation of Bax and Bak, downregulation of Bcl-XL and dysfunction of mitochondria in chondrosarcoma cells. Honokiol triggered endoplasmic reticulum (ER) stress, as indicated by changes in cytosol-calcium levels. We also found that honokiol increased the expression and activities of glucose-regulated protein 78 (GRP78) and calpain. Transfection of cells with GRP78 or calpain siRNA reduced honokiol-mediated cell apoptosis in JJ012 cells. Importantly, animal studies have revealed a dramatic 53% reduction in tumor volume after 21days of treatment. This study demonstrates that honokiol may be a novel anti-cancer agent targeting chondrosarcoma cells. 2009 Elsevier Ireland Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19880244 DOI: 10.1016/j.canlet.2009.08.032
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679